DMPK & Preformulation
- High throughput ADME screening
- In vitro/in vivo DMPK studies from project start to IND/NDA (rodents and non-rodents)
- PK/PD analysis, modelling and simulations
- Human PK analysis and PK/DDI prediction
- Non-clinical/clinical bioanalysis and metabolite ID identification for multiple modalities
- Physicochemical profiling
- Preformulation studies
- Parenteral application studies

Chemistry
- Medicinal Chemistry for Hit identification, Lead generation and Lead optimization
- Design and synthesis of novel compounds for multiple target classes such as kinase, GPCR, channel, PPI, etc.
- Design and synthesis of peptide and nucleic acid
- Computational medicinal chemistry (SBDD, LBDD)
- Cheminformatics
- High-throughput parallel synthesis
- Synthetic route development and scale-up synthesis
- Labelled compound and metabolite synthesis
- Analytical chemistry

Nonclinical safety
- Discovery toxicology & pathology
- GLP toxicology & safety pharmacology for IND (rodents and non-rodents)
- Investigative toxicology & molecular pathology
- Tumorigenic assessment of cell-therapy products

Animal care
(Collaboration with on site animal care team)
- AAALAC and GLP Accredited Animal Care & Use program
- Veterinary service
- Animal breeding

Axcelead Drug Discovery Partners, Inc.

Access Map

From JR Ofuna Station:
Take the Enoden Bus bound for Fujisawa-eki Kitaguchi at the East Exit Bus Terminal Stop No.2, and get off at Takeda Yakuhin-mae. (Approx: 15mins)
Taxi: About 10 minutes from west-site Taxi Terminal Stop after exiting the South Exit of JR Line

From JR Fujisawa Station:
Take the Enoden Bus bound for Ofuna-eki Higashiguchi at the North Exit Bus Terminal Stop No.9, and get off at Takeda Yakuhin-mae. (Approx: 15mins)
Taxi: About 10 minutes from Taxi Terminal Stop after exiting the North Exit of JR Line

From Tokyo:
About 11km from the Kamiyabe Interchange on the Yokohama By-pass via Route 1 Harajuku

From Odawara:
About 6km from the Fujisawa Interchange on the Shin-ahman By-pass via Fujisawa-bashi
We are a market leading solution provider in the drug discovery space

Axcelead Drug Discovery Partners, Inc. will be a fully-independent subsidiary of Takeda that combines scientific excellence, world-class IP protection and state-of-the-art GLP*1 accredited facilities and capabilities to deliver integrated end-to-end early discovery

We will be Japan’s first provider of integrated drug discovery services - a one stop-shop for Research providing:

- Integrated drug-discovery on a risk-shared basis aligned to delivering tangible innovative outcomes to clients
- Fee-for-service and FTE-based offerings to flexibly accessing drug-discovery expertise and technologies
- Consultancy support

We leverage state-of-the-art facilities/capabilities to deliver holistic discovery services tailored to each customer’s needs

Value proposition
1. Scientific powerhouse with expertise in a range of therapeutic areas - CNS, CV/Metabolism, GI, Oncology, Immunology and other TAs
2. State-of-the-art operations to deliver solutions across the spectrum of target-IND
3. Market leading HTS platform and infrastructure – one of the largest chemical libraries and comprehensive HTS capabilities in the industry

Vision
- Become the best partner of choice for pharma and biotechs delivering innovative medicines
- Deliver tangible value-creation in a cost-effective manner by exceeding client expectations
- Bridge the gap between academia and Pharma by enhancing the biotechnology ecosystem in Japan

We will offer a comprehensive set of best-in-class capabilities to meet a range of customer needs

- Co-location of all services – driving quality science and integrated insights
- One of the largest chemical libraries for HTS in the industry
- Access to industry’s best scientific talent
- AAALAC*2 and GLP accreditations
- Completely independent entity – highest standards of IP protection and confidentiality

*Biology
- Vitro/in vivo pharmacology for multiple therapeutic areas
- Molecular biology
- Multi-omics analysis using gene-edited cells/animals, patient samples and clinical information
- Bioinformatics
- Proprietary animal models, such as transgenic, knock out, humanized and immunodeficiency

*Research consulting
Over 200 highly qualified discovery scientists, headed by industry leaders with ~30 years’ experience

*Screening
- High-quality and diversified compound library
- Compound library management (fully automated, state-of-the-art robotics)
- High throughput screening (~300,000 data points/day) for multiple target classes
- In vitro assay and compound profiling in Hit to Lead/Lead Generation/Lead Optimization stage
- Protein science, Structural Biology & Biophysics

We leverage state-of-the-art facilities/capabilities to deliver holistic discovery services tailored to each customer’s needs

Value proposition
1. Scientific powerhouse with expertise in a range of therapeutic areas - CNS, CV/Metabolism, GI, Oncology, Immunology and other TAs
2. State-of-the-art operations to deliver solutions across the spectrum of target-IND
3. Market leading HTS platform and infrastructure – one of the largest chemical libraries and comprehensive HTS capabilities in the industry

Vision
- Become the best partner of choice for pharma and biotechs delivering innovative medicines
- Deliver tangible value-creation in a cost-effective manner by exceeding client expectations
- Bridge the gap between academia and Pharma by enhancing the biotechnology ecosystem in Japan

We will offer a comprehensive set of best-in-class capabilities to meet a range of customer needs

- Co-location of all services – driving quality science and integrated insights
- One of the largest chemical libraries for HTS in the industry
- Access to industry’s best scientific talent
- AAALAC*2 and GLP accreditations
- Completely independent entity – highest standards of IP protection and confidentiality

*Biology
- Vitro/in vivo pharmacology for multiple therapeutic areas
- Molecular biology
- Multi-omics analysis using gene-edited cells/animals, patient samples and clinical information
- Bioinformatics
- Proprietary animal models, such as transgenic, knock out, humanized and immunodeficiency

*Research consulting
Over 200 highly qualified discovery scientists, headed by industry leaders with ~30 years’ experience

*Screening
- High-quality and diversified compound library
- Compound library management (fully automated, state-of-the-art robotics)
- High throughput screening (~300,000 data points/day) for multiple target classes
- In vitro assay and compound profiling in Hit to Lead/Lead Generation/Lead Optimization stage
- Protein science, Structural Biology & Biophysics